How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts

Simply Wall St.03-16 06:16

In recent days, CG Oncology drew attention as multiple research firms updated their views on the company, while it expanded its at-the-market stock offering to up to US$550 million to support progress...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619148606?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-16 06:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619148606","market":"us","top_or_hot":-1,"title":"How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts","media":"Simply Wall St.","content":"<div>\n<p>In recent days, CG Oncology drew attention as multiple research firms updated their views on the company, while it expanded its at-the-market stock offering to up to US$550 million to support progress...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/how-investors-may-respond-to-cg-oncology-cgon-expanding-atm\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-16 06:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/how-investors-may-respond-to-cg-oncology-cgon-expanding-atm><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent days, CG Oncology drew attention as multiple research firms updated their views on the company, while it expanded its at-the-market stock offering to up to US$550 million to support progress...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/how-investors-may-respond-to-cg-oncology-cgon-expanding-atm\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/how-investors-may-respond-to-cg-oncology-cgon-expanding-atm","article_id":"2619148606","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/how-investors-may-respond-to-cg-oncology-cgon-expanding-atm","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619148606","pubTimestamp":1773613002,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent days, CG Oncology drew attention as multiple research firms updated their views on the company, while it expanded its at-the-market stock offering to up to US$550 million to support progress toward a Biologics License Application for its bladder cancer therapy candidate, cretostimogene.\nAnalysts pointed to recent clinical and market validation in intermediate-risk non-muscle invasive bladder cancer and CG Oncology’s advancing PIVOT-006 trial as important factors shaping how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4135":"资产管理与托管银行","CG":"凯雷","BK4211":"区域性银行","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","ISBC":"投资者银行","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","CGON":"CG Oncology Inc."},"translate_title":"投资者如何应对CG Oncology(CGON)扩大ATM产品以推进Cretostimogene BLA工作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CG":1.5,"CGON":1.5,"ISBC":1.5},"content_text":"In recent days, CG Oncology drew attention as multiple research firms updated their views on the company, while it expanded its at-the-market stock offering to up to US$550 million to support progress toward a Biologics License Application for its bladder cancer therapy candidate, cretostimogene. Analysts pointed to recent clinical and market validation in intermediate-risk non-muscle invasive bladder cancer and CG Oncology’s advancing PIVOT-006 trial as important factors shaping how investors assess the company’s position in this treatment area. With the shares posting a 7-day gain and ongoing work on cretostimogene, we’ll explore how this financing and analyst attention influence CG Oncology’s investment narrative. We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementWhat Is CG Oncology's Investment Narrative?To own CG Oncology, you really have to believe that cretostimogene can translate its bladder cancer data package into a successful Biologics License Application and, eventually, a commercial product that justifies years of heavy losses. The latest news, with research firms lifting their targets and CG Oncology expanding its at-the-market program to up to US$550 million, reinforces that the near term story is still all about clinical milestones, especially the PIVOT-006 readout and BLA progress. The extra capital could ease near-term funding concerns and support trial execution, but it also raises the prospect of further dilution at a time when the company has only US$4.04 million in revenue and a US$160.99 million annual loss. That mix of clinical momentum, analyst enthusiasm and balance sheet risk is what now defines the short term setup. However, there is one dilution-related risk here that investors should not overlook.\n\nCG Oncology's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesCGON 1-Year Stock Price Chart The Simply Wall St Community currently has 1 fair value estimate clustered around US$304.14, far above the current share price. Set that against the recent funding expansion and ongoing losses, and you can see why different market participants might read the same CG Oncology story very differently.Explore another fair value estimate on CG Oncology - why the stock might be worth just $304.14!The Verdict Is YoursDisagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your CG Oncology research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free CG Oncology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CG Oncology's overall financial health at a glance.Seeking Other Investments?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Uncover the next big thing with 32 elite penny stocks that balance risk and reward.Find 48 companies with promising cash flow potential yet trading below their fair value.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619148606","isCrawlerRequest":true}